Topical application of FTY720 and cyclosporin A prolong corneal graft survival in mice

Molecular Vision

Volumn 18, Issue , 2012, Pages 624-633

  Liu, Yong ^a,b   Jiang, Jingjing ^a   Xiao, He ^c   Wang, Xiaokui ^d   Li, Yan ^c   Gong, Yubo ^a   Wang, Dajiang ^a   Huang, Yifei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b AIR FORCE GENERAL HOSPITAL   (China)

^c INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^d BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOKINE; EYE DROPS; FINGOLIMOD; GAMMA INTERFERON; INTERLEUKIN 2; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CD4 LYMPHOCYTE PERCENTAGE; CD4+ CD25+ FOXP3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CERVICAL LYMPH NODE; CONTROLLED STUDY; CORNEA TRANSPLANTATION; DOWN REGULATION; DRUG EFFECT; FLOW CYTOMETRY; GEL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GRAFT RECIPIENT; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE;

ADMINISTRATION, OPHTHALMIC; ANIMALS; CELL PROLIFERATION; CORNEA; CORNEAL TRANSPLANTATION; CYCLOSPORINE; CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; GELS; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OPHTHALMIC SOLUTIONS; PROPYLENE GLYCOLS; SPHINGOSINE; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84859017451     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ 2001; 79:214-21. [PMID: 11285665]
2. Rocha G, Deschenes J, Rowsey JJ. The immunology of corneal graft rejection. Crit Rev Immunol 1998; 18:305-25. [PMID:9704192]
3. Williams KA, Lowe M, Bartlett C, Kelly TL, Coster DJ, All C. Risk factors for human corneal graft failure within the Australian corneal graft registry. Transplantation 2008; 86:1720-4. [PMID: 19104411]
4. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection. Their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol 1981; 99:599-604. [PMID: 7013739]
5. Maguire MG, Stark WJ, Gottsch JD, Stulting RD, Sugar A, Fink NE, Schwartz A. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology 1994; 101:1536-47. [PMID:8090456]
6. Williams KA, Roder D, Esterman A, Muehlberg SM, Coster DJ. Factors predictive of corneal graft survival. Report from the Australian Corneal Graft Registry. Ophthalmology 1992; 99:403-14. [PMID: 1565452]
7. Panda A, Vanathi M, Kumar A, Dash Y, Priya S. Corneal graft rejection. Surv Ophthalmol 2007; 52:375-96. [PMID:17574064]
8. Niederkorn JY. Immune mechanisms of corneal allograft rejection. Curr Eye Res 2007; 32:1005-16. [PMID:18085464]
9. Chauhan SK, Saban DR, Lee HK, Dana R. Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J Immunol 2009; 182:148-53. [PMID:19109145]
10. Cunnusamy K, Paunicka K, Reyes N, Yang W, Chen PW, Niederkorn JY. Two different regulatory T cell populations that promote corneal allograft survival. Invest Ophthalmol Vis Sci 2010; 51:6566-74. [PMID: 20702818]
11. Inoue K, Kimura C, Amano S, Sato T, Fujita N, Kagaya F, Kaji Y, Tsuru T, Araie M. Long-term outcome of systemic cyclosporine treatment following penetrating keratoplasty. Jpn J Ophthalmol 2001; 45:378-82. [PMID: 11485770]
12. Shimazaki J, Den S, Omoto M, Satake Y, Shimmura S, Tsubota K. Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. American Journal of Ophthalmology 2011; 152:33-9e1. [PMID:21570054]
13. Suzuki S, Enosawa S, Kakefuda T, Shinomiya T, Amari M, Naoe S, Hoshino Y, Chiba K. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces longterm graft acceptance in rat and dog allotransplantation. Transplantation 1996; 61:200-5. [PMID: 8600623]
14. Hanessian S, Charron G, Billich A, Guerini D. Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors. Bioorg Med Chem Lett 2007; 17:491-4. [PMID: 17070046]
15. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277:21453-7. [PMID: 11967257]
16. Salvadori M, Budde K, Charpentier B, Klempnauer J, Nashan B, Pallardo LM, Eris J, Schena FP, Eisenberger U, Rostaing L, Hmissi A, Aradhye S, FTY720 0124 Study Group. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 2006; 6:2912-21. [PMID: 17061999]
17. Li Q, Li F. Effects of different dose of FTY720 on lymphocyte cell cycle arrest in cardiac transplantation model of rats. Immunopharmacol Immunotoxicol 2010; 32:680-7. [PMID:20201753]
18. Sedláková K, Muckersie E, Robertson M, Filipec M, Forrester JV. FTY720 in corneal concordant xenotransplantation. Transplantation 2005; 79:297-303. [PMID: 15699759]
19. Mayer K, Birnbaum F, Reinhard T, Reis A, Braunstein S, Claas F, Sundmacher R. FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations. Br J Ophthalmol 2004; 88:915-9. [PMID:15205237]
20. Zhang EP, Muller A, Ignatius R, Hoffmann F. Significant prolongation of orthotopic corneal-graft survival in FTY720-treated mice. Transplantation 2003; 76:1511-3. [PMID:14657695]
21. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, Group TS. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362:402-15. [PMID: 20089954]
22. Zhang EP, Schrunder S, Hoffmann F. Orthotopic corneal transplantation in the mouse-a new surgical technique with minimal endothelial cell loss. Graefes Arch Clin Exp Ophthalmol 1996; 234:714-9. [PMID: 8950593]
23. Larkin DF, Calder VL, Lightman SL. Identification and characterization of cells infiltrating the graft and aqueous humour in rat corneal allograft rejection. Clin Exp Immunol 1997; 107:381-91. [PMID: 9030879]
24. Xie Y, Sun HX, Li D. Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen. Vaccine 2009; 27:757-64. [PMID: 19041358]
25. Zhang JL, Sun DJ, Hou CM, Wei YL, Li XY, Yu ZY, Feng JN, Shen BF, Li Y, Xiao H. CD3 mAb treatment ameliorated the severity of the cGVHD-induced lupus nephritis in mice by up-regulation of Foxp3+ regulatory T cells in the target tissue: kidney. Transpl Immunol 2010; 24:17-25. [PMID: 20850528]
26. Küchle M, Cursiefen C, Nguyen NX, Langenbucher A, Seitz B, Wenkel H, Martus P, Naumann GO. Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch Clin Exp Ophthalmol 2002; 240:580-4. [PMID: 12136292]
27. Xie L, Shi W, Wang Z, Bei J, Wang S. Prolongation of corneal allograft survival using cyclosporine in a polylactide-coglycolide polymer. Cornea 2001; 20:748-52. [PMID:11588429]
28. Alalwani H, Omer Saleh B, Rocher N, Renard G, Bourges JL, Legeais JM. Advantages and limits of multiple grafts (third keratoplasty) under local cyclosporin 2%. J Fr Ophtalmol 2010; 33:710-4. [PMID: 21093105]
29. Bourges JL, Lallemand F, Agla E, Besseghir K, Dumont JM, Benezra D, Gurny R, Behar-Cohen F. Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats. Mol Vis 2006; 12:1461-6. [PMID: 17167400]
30. Poon A, Constantinou M, Lamoureux E, Taylor HR. Topical Cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial. Clin Experiment Ophthalmol 2008; 36:415-21. [PMID: 18939344]
31. Sinha R, Jhanji V, Verma K, Sharma N, Biswas NR, Vajpayee RB. Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial. Graefes Arch Clin Exp Ophthalmol 2010; 248:1167-72. [PMID: 20414783]
32. Unal M, Yucel I. Evaluation of topical ciclosporin 0.05% for prevention of rejection in high-risk corneal grafts. Br J Ophthalmol 2008; 92:1411-4. [PMID: 18662913]
33. Premenko-Lanier M, Moseley NB, Pruett ST, Romagnoli PA, Altman JD. Transient FTY720 treatment promotes immunemediated clearance of a chronic viral infection. Nature 2008; 454:894-8. [PMID: 18704087]
34. Sawicka E, Dubois G, Jarai G, Edwards M, Thomas M, Nicholls A, Albert R, Newson C, Brinkmann V, Walker C. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ Tregulatory cells and enhances their functional activity. J Immunol 2005; 175:7973-80. [PMID: 16339533]
35. Commodaro AG, Peron JP, Lopes CT, Arslanian C, Belfort R Jr, Rizzo LV, Bueno V. Evaluation of experimental autoimmune uveitis in mice treated with FTY720. Invest Ophthalmol Vis Sci 2010; 51:2568-74. [PMID: 20019358]
36. Sehrawat S, Rouse BT. Anti-inflammatory effects of FTY720 against viral-induced immunopathology: role of druginduced conversion of T cells to become Foxp3+ regulators. J Immunol 2008; 180:7636-47. [PMID: 18490766]
37. Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, Cutler C, Ho VT, Alyea EP, Antin JH, Soiffer RJ, Ritz J. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest 2010; 120:1479-93. [PMID:20389017]
38. Ochando JC, Yopp AC, Yang Y, Garin A, Li Y, Boros P, Llodra J, Ding Y, Lira SA, Krieger NR, Bromberg JS. Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. J Immunol 2005; 174:6993-7005. [PMID: 15905542]
39. Schneider MA, Meingassner JG, Lipp M, Moore HD, Rot A. CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells. J Exp Med 2007; 204:735-45. [PMID:17371928]
40. Daley SR, Ma J, Adams E, Cobbold SP, Waldmann H. A key role for TGF-beta signaling to T cells in the long-term acceptance of allografts. J Immunol 2007; 179:3648-54. [PMID: 17785800]
41. Lu L, Ma J, Wang X, Wang J, Zhang F, Yu J, He G, Xu B, Brand DD, Horwitz DA, Shi W, Zheng SG. Synergistic effect of TGF-beta superfamily members on the induction of Foxp3+ Treg. Eur J Immunol 2010; 40:142-52. [PMID: 19943263]
42. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006; 24:209-26. [PMID: 16551248]
43. Kobayashi T, Momoi Y, Iwasaki T. Cyclosporine A inhibits the mRNA expressions of IL-2, IL-4 and IFN-gamma, but not TNF-alpha, in canine mononuclear cells. J Vet Med Sci 2007; 69:887-92. [PMID: 17917372]
44. Tian L, Stepkowski SM, Qu X, Wang ME, Wang M, Yu J, Kahan BD. Cytokine mRNA expression in tolerant heart allografts after immunosuppression with cyclosporine, sirolimus or brequinar. Transpl Immunol 1997; 5:189-98. [PMID: 9402685]
45. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 1992; 89:3686-90. [PMID: 1373887]